Ohno S, et al. - Between January 2007 and January 2010, authors analyzed 656 cases to assess the effectiveness and long-term safety of infliximab in subjects with refractory uveoretinitis in Behcet’s disease (RUBD) in Japan. Using the Wilcoxon signed-rank test, they compared the frequency of ocular attacks before and after infliximab treatment. They observed infections as the most common adverse drug reactions (ADRs) and serious ADRs viz, 11.89% and 3.66%. Only 2 cases were found infected with tuberculosis and Pneumocystis jirovecii in one. They identified the comorbid respiratory disease, history of allergic disease, and concomitant use of glucocorticoids as independently associated factors for infections. Overall, they considered infliximab treatment, a good treatment option for RUBD with good tolerability and efficiency in this large-scale, long-term postmarketing surveillance (PMS).